CoChat

Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy

The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.

Abstract

Interferon (IFN)-alpha is a cytokine of the innate immune response that is well known for inducing behavioral alterations and has been used to study effects of cytokines on the nervous system. Limited data, however, are available on the sites of action of IFN-alpha within the brain and their relationship with specific IFN-alpha-induced symptoms. Using a longitudinal design, whole-brain metabolic activity as assessed by fluorine-18-labeled fluorodeoxyglucose uptake and positron emission tomography was examined before and 4 weeks after IFN-alpha administration in patients with malignant melanoma. Changes in metabolic activity in relevant brain regions were then correlated with IFN-alpha-induced behavioral changes. IFN-alpha administration was associated with widespread bilateral increases in glucose metabolism in subcortical regions including the basal ganglia and cerebellum. Decreases in dorsal prefrontal cortex glucose metabolism were also observed. Prominent IFN-alpha-induced behavioral changes included lassitude, inability to feel, and fatigue. Correlational analyses revealed that self-reported fatigue (specifically as assessed by the 'energy' subscale of the Visual Analog Scale of Fatigue) was associated with increased glucose metabolism in the left nucleus accumbens and putamen. These data indicate that IFN-alpha as well as other cytokines of the innate immune response may target basal ganglia nuclei, thereby contributing to fatigue-related symptoms in medically ill patients.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1301362

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 229

Metadata

Authors
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H.
Affiliations
Emory University (US)
Corresponding author
Miller, Andrew H
Venue
Neuropsychopharmacology
Published
2007-02-28
Volume
32
Issue
11
Pages
2384-2392
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2072184805
Cited by
229
References
70
Citations by year
2026: 7 · 2025: 10 · 2024: 7 · 2023: 10 · 2022: 5 · 2021: 9 · 2020: 15 · 2019: 10 · 2018: 17 · 2017: 12 · 2016: 18 · 2015: 17 · 2014: 8 · 2013: 14 · 2012: 22
FWCI
4.33
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion)
Funders
  • Abbott Laboratories
  • American Foundation for Suicide Prevention
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • American Psychiatric Institute for Research and Education
  • Emory University
  • National Alliance for Research on Schizophrenia and Depression
  • ACADIA Pharmaceuticals
  • Neurocrine Biosciences
  • Centers for Disease Control and Prevention
  • Pfizer Pharmaceuticals
  • National Institute of Mental Health (MH 067990, R01MH067990, MH069124, K05MH069124)
  • National Institute on Drug Abuse (K08DA000367, DA-00367)
  • National Institute of Biomedical Imaging and Bioengineering (EB002635, R01EB002635)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
Keywords
interferon-alpha, basal ganglia, fatigue, glucose metabolism, nucleus accumbens, putamen, cerebellum, prefrontal cortex, melanoma, lassitude, immune-related adverse events
MeSH terms
Adult, Basal Ganglia, Behavioral Symptoms, Brain Mapping, Female, Humans, Immunologic Factors, Longitudinal Studies, Male, Middle Aged, Fatigue Syndrome, Chronic, Interferon-alpha, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.